Preoperative Vascular Endothelial Growth Factor Levels as a Prognostic Marker for Stage II or III Colorectal Cancer Patients

Kemik, Özgür; Kemik, Ahu Sarbay; Sümer, Aziz; Pürisa, Sevim; Dülger, Ahmet Cumhur; Beğenik, Hüseyin; Hasırcı, İsmail; Tüzün, Sefa

doi:10.4137/cgm.s7113

Cited by 3 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the study in laryngeal cancer by Lv et al (2011) found that serum VEGF-A level was elevated in advanced T-stage patients (T3-4) in comparison to early T-stage (T1-2); and it was also elevated in patients with metastatic disease in comparison to non-metastatic disease. Similar study by Kemik et al (2011) in colorectal cancer, observed significantly higher level of serum VEGF-A in (T3-4) vs early T-stage (T1-2); and it was also elevated in patients with metastatic disease as compared to non-metastatic disease. This conflicting result shows necessity of further evaluation of Serum VEGF-A level in large cohort of patients.…”

Section: Serum Vegf-a Level and Treatment Responsesupporting

confidence: 67%

Serum Vascular Endothelial Growth Factor-A (VEGF-A) as a Biomarker in Squamous Cell Carcinoma of Head and Neck Patients Undergoing Chemoradiotherapy

Srivastava

Gara²,

Rastogi³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Serum Vegf-a Level and Treatment Responsesupporting

confidence: 67%

Serum Vascular Endothelial Growth Factor-A (VEGF-A) as a Biomarker in Squamous Cell Carcinoma of Head and Neck Patients Undergoing Chemoradiotherapy

Srivastava

Gara²,

Rastogi³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Several clinical trials in CRC patients indicate an inverse relationship between the concentration of VEGF-A in serum or tumor tissue and the clinical outcome [ 9 – 11 ]. Furthermore, certain VEGF-A polymorphisms have been associated with altered VEGF-A production or promoter activity, causing variability in response to treatment [ 12 – 14 ].…”

Section: Introductionmentioning

confidence: 99%

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients

Panoilia

Schindler

Samantas

et al. 2015

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Purpose To characterize the population pharmacokinetics of bevacizumab, its binding properties to VEGF165 and the effect of demographic data and VEGF-A polymorphisms on the interplay between bevacizumab serum pharmacokinetics and VEGF165 serum concentrations in patients with colorectal cancer stage IV.MethodsBevacizumab and VEGF165 data were collected from 19 adult patients with metastatic colorectal cancer enrolled in an observational clinical study. Bevacizumab was administered with one of the following combinations: 5-FU/Leucovorin/Irinotecan, 5-FU/Leucovorin/Oxaliplatin, Capecitabine/Irinotecan at doses ranging from 5 to 10 mg/kg every 2 or 3 weeks. Data analysis was performed using nonlinear mixed-effects modeling implemented in NONMEM 7.3.ResultsA target-mediated drug disposition model adequately described bevacizumab concentration changes over time and its binding characteristics to VEGF165. The estimated clearance of bevacizumab was 0.18 L/day, the free VEGF165 levels at baseline were 212 ng/L, and the elimination rate constant of free VEGF165 was 0.401 day−1. Body weight was allometrically included in all PK parameters.ConclusionThe final model adequately described the pre- and post-dose concentrations of total bevacizumab and free VEGF165 in patients with colorectal cancer. Model parameters were consistent with those previously reported for patients with solid tumors. Correlations between the binding affinity of bevacizumab and the VEGF-2578C/A and VEGF-634G/C polymorphisms were noticed.Electronic supplementary materialThe online version of this article (doi:10.1007/s00280-015-2701-3) contains supplementary material, which is available to authorized users.

show abstract

“…Several studies reported that serum VEGF is an independent prognostic factor [63][64][65][66]. It has been shown [67] that increased preoperative circulating VEGF levels cor-relate with factors reflecting disease progression including tumor size, and nodal and distant metastases in colorectal cancer.…”

Section: Discussionmentioning

confidence: 99%

Thymoquinone Suppresses Cellular Proliferation, Inhibits VEGF Production and Obstructs Tumor Progression and Invasion in the Rat Model of DMH-Induced Colon Carcinogenesis

Asfour¹,

Almadi²,

Haffar³

2013

View full text Add to dashboard Cite

A myriad of medicinal effects has been attributed to Thymoquinone (TQ), the major biological-active component of Nigella sativa. TQ has been shown to exhibit potent anti-tumor activities. The present work was undertaken to further explore TQ’s chemopreventive efficacy against 1, 2-dimethylhydrazine (DMH)-induced colon carcinogenesis in the rat model through a two-phase study (initiation and post-initiation) and to evaluate its potential impact on tumor progression and invasion in vivo. TQ treatment in the initiation phase significantly reduced tumor incidence, multiplicity and mean tumor volume. However, although mean tumor volume and multiplicity were decreased upon TQ treatment in the post-initiation phase, TQ did not reduce incidence significantly. Cellular proliferation, as assessed by expression of colonic PCNA, was shown to be inhibited in consequence to TQ treatment in both phases, with a more pronounced reduction in the initiation phase. In addition, our results demonstrated an appreciable negative impact of TQ on vascular endothelial growth factor (VEGF) production in tumor-bearing rats. Furthermore, we provided evidence that TQ-treatment, in both phases, tended to considerably suppress tumor progression and invasion. Taken together, the present study demonstrated that TQ, at an orally daily dose of 10 mg/kg, has a chemopreventive effect in the initiation phase, and has the potential to attenuate tumor burden, suppress progression of pre-neoplastic lesions and to inhibit tumor growth in the post-initiation phase of DMH-induced colon carcinogenesis, We surmise that such effects of TQ may be due to suppression of cellular proliferation and inhibition of VEGF production. The results could provide an effective chemopreventive approach in the primary prevention of colon cancer in humans in the next future, and illuminate a promising horizon to combat progression of benign colonic pre-neoplastic lesions into malignant metastatic tumors and to manage colon cancer.

show abstract

Preoperative Vascular Endothelial Growth Factor Levels as a Prognostic Marker for Stage II or III Colorectal Cancer Patients

Cited by 3 publications

References 33 publications

Serum Vascular Endothelial Growth Factor-A (VEGF-A) as a Biomarker in Squamous Cell Carcinoma of Head and Neck Patients Undergoing Chemoradiotherapy

Serum Vascular Endothelial Growth Factor-A (VEGF-A) as a Biomarker in Squamous Cell Carcinoma of Head and Neck Patients Undergoing Chemoradiotherapy

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients

Thymoquinone Suppresses Cellular Proliferation, Inhibits VEGF Production and Obstructs Tumor Progression and Invasion in the Rat Model of DMH-Induced Colon Carcinogenesis

Contact Info

Product

Resources

About